Belite Bio (BLTE) Other financing activities (2023 - 2025)

Belite Bio's (BLTE) quarterly Other financing activities came in at $1.4 million in Q4 2025, down 96.24% year-on-year from $36.9 million in Q4 2024, and down 96.24% quarter-over-quarter from $36.9 million in Q4 2024.

Belite Bio (BLTE) Other financing activities (2023 - 2025) Analysis & Trends

Belite Bio's Other financing activities history runs 3 years deep, the most recent figure standing at $1.4 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.39 Mn
Dec 31, 2025 1.39 Mn
Dec 31, 2024 36.88 Mn
Dec 31, 2024 36.88 Mn
Dec 31, 2023 21.65 Mn
Dec 31, 2023 21.65 Mn